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être difficile à traiter par les maladies associées qui
peuvent se développer à tout moment et être déli-
cates à diagnostiquer à leur début.
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What to do when they occur
COSTANTINOS MANDRAGOS, PANTELIA
NASOPOULOU
ICU “Red Cross Hospital of Athens”
What to do when the Hospital Acquired Pneu-
monia (HAP) or Nosocomial Pneumonia (N P)
occurs? This a difficult question for the intesivists
when they are infront to this major problem. Des-
pite the advances in antimicrobial chemotherapy,
successful treatment of patients with HAP or NP
remains a difficult and complex issue. The intensi-
vist has obligation to his patients (ought to suggest
the newest and strongest antibiotic because it is
necessary to be treated immediately, especially
when the HAP is life threatening), and to the com-
munity (ought to protect the emergence of antibio-
tic resistance with the avoidance of unnecessary use
of antibiotics) as well. It is well known, that the
Ventilator Associated Pneumonia (VAP) is inclu-
ded among the Hospital Acquired Pneumonias or
Nosocomial Pneumonia types.
Therefore, the early identification of the HAP
and the accurate selection of antimicrobials agents
for the initial treatment represent important clinical
goals , since it appears that appropriate treatment
of the infection might have a major role in reducing
HAP associated mortality and morbidity1. So the
infection guided directed antimicrobial chemother-
apy (IDAC) must be started as soon as possible.
The term IDAC defines the administration of anti-
microbials for a specific clinically localized source
of infection (e.g. pneumonia, urinary tract, wound,
blood stream). But before the IDAC is started, the
following questions have to be answered by the
physician in order to establish criteria to guide re-
stricting IDAC without causing patient harm.
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QUESTION 1
What is the patient past medical history? Be-
cause there is a direct connection among the pa-
tients past medical history and the microorganisms
involved.
It is known that in the presence of acute or
chronic alcoholism pneumococcus, S. aureus, H.
influenzae, K. pneumonia are implicated.
Tuberculosis, Chronic Obstructive Pulmonary
Disease (COPD): Pneumococcus H. influenzae, M.
Catarrhalis.
Recent viral infection: Pneumonococcus, S. au-
reus H. influenzae, gram negative bacilli.
Nursing home, age > 75 year: Gram negative
bacilli, Pneumococus, H. Influenzae, aspiration
(anaerobes).
AIDS (risk group: IV drug abuser, hemophilia,
hommosexual): Pneumococcus, Salmonella, cy-
tomegavirus, H. Influeanzae, Cryptococcus, Pneu-
mocystis carinii.
High risk for aspiration: Anaerobes, gram nega-
tive bacilli.
Underlying cardiac disease: Pneumococcus,
gram negative bacilli.
Neutropenia: P. aeruginosa, Aspergillus, gram
negative bacilli2.
QUESTION 2
It is very crusial to identify the onset of the HAP.
Early or late onset due to different microbial strains
involved.
Community – acquired pathogens, such as H.
Influeanzae, Pneumococcus of methicillin suscepti-
ble, S. aureus often are responsible for the early
onset of HAP occurring in the first four days of
hospitalization. In these cases pathogens with strong
intrinsic or acquired antimicrobial resistance are
rarely causative.
Late onset HAP defined as lower respiratory
tract infection occurring after 5th day of hospitaliza-
tion is caused often by aerobic gram – negative
bacilli: Pseudomonas Aeruginosa, Enterobacte-
riaceae or Acinetobacter or Methicillin Resistance
Staph. Aureus (MRSA).
Late onset pneumonia is due to P. aeruginosa
Acinetobacter, MRSA in 30% – 71% of cases and
Enterobacteriaceae3.
QUESTION 3
What is the hospital’s predominant microbial
flora as well as the local antibiotic susceptibility
patterns of pathogens, it has be taken into account,
before the antimicrobial chemotherapy is initia-
ted. The reason is that microbial flora and antibio-
tics susceptibility patterns are different depending
on the hospital and the general policy. (how the
antibiotics have been administered, what kind are
the patients admitted to the ICU etc.). For these
reasons it would be prudent to collect and study
these data just before the initiation of antimicro-
bial chemotherapy.
QUESTION 4
Pharmacokinetics. Adequate drug levels have
to be achieved in the lung, which it is possible with
the use antibiotics like Cephalosporins or Carba-
penems or Piperacillin/Tozabactam or Fluoroqui-
nolones.
The aminoglycosides problem: Despite the ex-
tensive clinical use, aminoglycosaids are not used
as a monotherapy but in combination with a ²-actam
antibiotic (this combination theoretically reduces the
emergence of resistance and extends the spectrum
of activity). However the benefit of aminoglycosides
use in H.A.P remains controversial. Aminoglyco-
sides penetrate poorly into bronchopulmonary se-
cretions and the lung, are inactivated under condi-
tions of low pH and have serious potential toxici-
ties (particularly nephrotoxicity)4.
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There are not enough data supporting the ex-
tend use of aminoglycosides for the treatment of
HAP. In one series of 78 patients with HAP caused
by Gram-negative bacteria, clinical response to
therapy was more rapid when target ratios of maxi-
mal concentration of aminoglycide in serum to the
minmal inhibitory concentration were achieved5. In
another controlled, multicenter, randomized study,
clinical response rates were highest with ceftazidime
plus long-course (9 days) amikacin treatment. The
benefit of the aminoglycoside was more pronounced
when P. aeroginosa was implicated6.
It seems, that the optimization of anminoglyco-
sides dosing may be critical for theto successful
treatment of severe H.A.P. caused by Gram-nega-
tive bacteria, but it needs a lot of caution due to the
toxicity particularly the nephrotoxicity, specially in
case of septic shock.
QUESTION 5
Is there any organ failure? What is the organ
failure? When the organ failure or organ dysfunc-
tion happened? It is very important for the intensi-
vist to be aware for the time that organ failure ap-
peared (before or after ICU admission). And if it
took place after the admission, what is the causa-
tive reason? However the doses have to be adjus-
ted in case of renal of liver failure. The doses of
antibiotics must be reviewed daily according to the
patient’s general condition and the results of antibi-
otics plasma levels.
QUESTION 6
Should any precaution be taken? Special care
must be taken in patients with a reduction in lean
body mass and an increase in fat (is it happen in the
elderly). The drug levels may rise if chosen on a per
kilogram basis.
In those with reduced serum albumin, free drug
concentration rise if the antibiotic is normally highly
bound to proteins. The sodium content of many
drugs especially the penicillin or Primaxin (imipe-
nem/silastatin sodium) may be important in patients
with renal or heart failure.
QUESTION 7
Are the anaerobic responsible for the HAP?
There are not clinical data supporting the adminis-
tration of antibiotics against anaerobes in patients
with suspected HAP or VAP. Marik and Careau
describe their experience in 185 cases of suspe-
cted aspiration pneumonia in 143 patients. Despite
the use of specific methods to isolate anaerobic
bacteria – anaerobia were isolated just in one case
of 75 episodes that were classified as aspiration
pneumonia. These results differ somewhat from
those of Dore and coworkers, that examined 130
patients with microbiologically documented VAP
using protected specimen brush (PSB) cultures and
rigorous anaerobic culturing techniques. In 30(23%)
patients PSB cultures resulted in anaerobic strains.
In 26 patients aerobic plus anaerobic agents where
isolated whereas just only anaerobic strains were
isolated in 4 patients from PSB cultures.
To date, no convincing clinical data are availa-
ble supporting the hypothesis that routine treatment
for anaerobic bacteria strains will improve the out-
come of patients with suspected HAP7,8.
QUESTION 8
Was there any previous antibiotic therapy? Pri-
or antibiotic use, particularly the use of broad spec-
trum antibiotics implicates the risk for colonization
or infection with P aeruginosa or Acinetobacter.
Two different studies support the aforementioned
remark. Fagon and al9 found that prior antimicrobi-
al chemotherapy markedly increased the rate of
VAP caused by P aeruginosa or Acinetobacter.
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These two pathogens accounted for 65% of VAP
cases among partients who had previously received
antibiotics, compared to 19% of VAP cases among
antibiotics-naïve patients. The second one by Rello
J et al10; in their study of 129 concecutive ICU pa-
tients with VAP, P aeruginosa was the causative
agent in 40% of patients who had previously re-
ceived antibiotics (within the preceding 10 days)
but in only 5% of those who had not received anti-
biotics.
A numerous of studies demonstrated  that prior
antibiotic use is the most common risk factor for
colonization and infection with MRSA. Other risk
factors for pneumonia due to MRSA include use
of corticosteroids, prolonged mechanical ventila-
tion (> 6 days) and COPD. Drug resistant patho-
gens are uncommon in the absence of previous
antibiotic therapy.
QUESTION 9
Is it a life threatening infection? If so, an antibi-
otic or a combination treatment should be utilized if
a combination of antibiotics is used, which is the
most appropriate?
Combination of antimicrobial agents theoretically
acting at different sites of the bacterial cell, may limit
resistance. The advantage of adding a second agent
has not been yet clarified in clinical trials
Better designed studies are necessary , in order
to prove, what usually takes place in the every day
practice, which is the use of combination treatment.
Combination of Aminoglycoside and ²-Lactam
antibiotics
Data supporting incremental benefit of aminogly-
cosides for the treatment of HAP are sparse. There
is proof from the existing studies, that there is be-
nefit by using this combination especially if the mi-
croorganism involved for the HAP is P aeruginosa.
Combination therapy with ²-Lactam
and Fluoroquinolones
Clinical data employing such combination are limi-
ted. Ciprofloxacin is the most active fluoroquinolone
in vitro against P. aeruginosa. There are limited data
evaluating levofloxacin for HAP.
WHAT ANTIBIOTIC MUST I SUGGEST?
After answering the critical questions, the anti-
microbial chemotherapy has to be initiated. The
suggested antimicrobial chemotherapy is the follow-
ing and depend upon the patients general condition
and the causative microorganisms
Non life threatening infection
Ceftazidime or Cefepime or Piperacillin/Ta-zo-
bactan or Carbapenems or Fluoroquinolones.
Pneumonia possibly caused by P. aeruginosa
Ceftazedime or Cefemime or Piperacillin/Ta-
zobactam or Carbapenems plus aminoglycoside or
fluoroquinolone.
Life threatening pneumonia
Ceftazedime or Cefepime or Piperacilline/Ta-
zobactam or Carbapenemes, plus Aminoglycoside
or Fluoroquinolones. (It is difficult for the clinician
to define exactly the life threatening pneumonia.
According to my opinion this must be based on the
patient general condition and the every hour eva-
luation).
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Pneumonia that Gram+cocci and Gram-bacilli
may be involved
Ceftazedime or Cefepime or Piperacillin/Ta-zo-
bactam or carbapenems or fluoroquinolones plus
teicoplanin or vancomycin
Life threatening pneumonia that Cram+cocci
and Gram-bacilli may be involved
Ceftazedime or Cefepime or Piperacillin/Ta-
obactem or carbapenems plus aminoglycoside or
fluoroquinolones plus teicoplanin or vancomyc.
High suspicon that a fungus is involved
Ceftazedime or Cefepinne or Piperacillin/Tao-
bactam or Carbapenems or fluoroquinolones plus
amphotericin.
WHEN THE ANTIBIOTIC TREATMENT SHOULD
BE CHANGED?
The evaluation of the response of pneumonia to
the initial antibiotic treatment should be performed
early, at 72 hours from diagnosis and should be
based on the assessment of the initial criteria of di-
agnosis and on additional scores of organ function.
Lack of response to the antibiotic treatment must
be suspected in the following circumstances: per-
sistence of fever, purulent tracheal secretion, leu-
kocytosis, progression of the radiographic pulmo-
nary infiltrate, lack of improvement of further im-
pairment of gas exchange.
Other parameters of organ dysfunction must be
assessed (creatine, bilirubin, platelets) in order to
rule out concomitant disorders that may contribute
to the failure to improve.
The first approach in case of non-response con-
sists of revising the antibiotic treatment based on
bacteriological results and adjusting the combina-
tion and dosage if necessary. Some microorganisms
that are not covered by the empirical treatment
(MRSA, fungi, Legionella spp, CMV) must be con-
sidered when risk factors are present (head trauma
for MRSA, immunocompromised condition for
fungi and viruses).
Other frequent causes of fever in critically ill
patients concomitant to pneumonia could be catheter
related sepsis, sinusitis or urinary tract infection. The
radiographic pulmonary infiltrate in critically ill pa-
tients could be related to ARDS, atelectasis, pul-
monary embolism or pulmonary oedema after lung
resection.
Causes of non response of pneumonia
to empirical antibiotics treatment
Inappropriate election/combination of antibioti-
cs, low dosage/serum level of antibiotics. Resistance
to antibiotics. Microorganisms not covered by the
initial treatment, superinfection. Infection other than
pneumonia like sinusitis, vascular catheter-related
sepsis, abdominal sepsis, pulmonary abscess, pleu-
ral effusion/empyema, urinary sepsis. Non infections
conditions, like ARDS, Atelectasis, BOOP, Pul-
monary embolism, Congestive heart failure, Pulmo-
nary oedema after lung recection, Drug related fe-
ver11.
ANTIBIOTICS BY CONTINUOUS INFUSION
There are ongoing studies where the antibiotics
have been given by continuous infusion. Vancomy-
cin is one of them. The results are promising. The-
oretical benefits of antibiotics infusion include greater
efficacy, reduction of drug expenditure, and the
possibility of shorter courses resulting in less risk of
the emergence of resistant bacteria12.
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NOVEL ROUTES OF ADMINISTRATION
Under evaluation is the administration of a ne-
bulized antibiotic in serious respiratory tract infec-
tions via endotracheals tubes. This method ensures
high antibiotic concentration at the site of infection,
minimizing systemic concentrations and their resul-
tant risk of toxicity13, but it is not clear yet, if this
route of administration increases the possibility of
resistance from microorganisms involved.
DURATION OF ANTIMICROBIAL
CHEMOTHERAPY
Duration of treatment of HAP should be indi-
vidualized, depending on the severity of illness, time
of onset, rapidity of clinical response and responsi-
ble pathogens.
To date, recommended duration of treatment of
HAP is based on multilobar involvement, cavitation
of necrotizing pneumonia or presence of P. aerugi-
nosa or Acinetobacter spp as responsible patho-
gen.
Clinical response (lower of temperature, radio-
logical score, leukocytosis, PaO2/FiO2 ratio, organ
failure, evolution of markers of inflammation) merits
to be evaluated. In the absence of factors identified
as strong arguments for deciding to stop antimicro-
bial therapy, clinical trials are required to evaluate
the prognostic value of clinical, bacteriological, of
inflammatory parameters14.
RECOMMENDATIONS FOR THE AVOIDANCE
OF INADEQUATE ANTIMICROBIAL CHEMO-
THERAPY ADMINISTRATION
It appears that antimicrobial therapy should be
administered early in the course of the infection, to
be most effective, especially prior to the develop-
ment of severe sepsis and septic shock
This will require a high index of suspicion on the
part of practitioners, caring for critically ill patients
in order to consider the diagnosis of infection in a
timely manner.
Due to the greater mortality associated with
delays in treatment, starting empiric antimicrobial
treatment at the first suspicion of infection in criti-
cally ill patients seems prudent in most instances.
In order to avoid increasing problems with drug-
resistant infections, the antimicrobial regimen should
subsequently be narrowed of discontinued altogeth-
er, based on the patient’s clinical course and cul-
ture results.
For patients with suspected infection who have
received prior antimicrobial therapy directed at
Gram-negative bacteria, subsequent empiric anti-
microbial treatment should include coverage of path-
ogens that may be potentially resistant to the earlier
administered antibiotics.
Although the routine use of combination antimi-
crobial therapy with dual agents directed against
Gram-negative bacteria is controversial, the admin-
istration of such therapy seems reasonable when
attempting to avoid the occurrence of inadequate
antimicrobial therapy due to antibiotic resistant
Gram-negative bacteria.
Similar recommendations for the empiric treat-
ment of Gram-positive bacteria cannot be made
since the number of available agents for antibiotic
resistant Gram-positive cocci is limited. The initial
empiric treatment with teicoplanin or vancomycin,
it seems sufficient in patient at risk for infection with
this specific pathogen15.
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